ストックスクリーナーアプリを入手
5.745
3.04%
0.145
Precigen Inc (PGEN) 最新ニュース
PGENPrecigen Inc Latest SEC Filings - Finviz
Insider Sell Alert: Harry Thomasian Sells 200,000 Shares of Prec - GuruFocus
Precigen CEO Helen Sabzevari sells $2.04m in PGEN stock - Investing.com
Precigen COO Rutul Shah sells $251,105 in company stock - Investing.com
Precigen (PGEN) COO sells 42,924 shares after option exercise - Stock Titan
Precigen CFO Harry Thomasian Jr. sells $1.1m in company stock - Investing.com Canada
[Form 4] PRECIGEN, INC. Insider Trading Activity - Stock Titan
Form 4 Precigen Inc For: 1 July By Investing.com - Investing.com Canada
Precigen COO Rutul Shah sells $251,105 in company stock By Investing.com - Investing.com Canada
Precigen (PGEN) CFO executes 200,000-share open-market sale under 10b5-1 plan - Stock Titan
Form 144 PRECIGEN For: 1 July By Investing.com - Investing.com Nigeria
PGEN (NASDAQ) affiliate files Rule 144 notice to sell 28,571 shares - Stock Titan
Does Precigen’s (PGEN) Russell Value Index Exit Signal a Shifting Investor Base or Story? - simplywall.st
[144] PRECIGEN, INC. SEC Filing - Stock Titan
Form 144 PRECIGEN For: 29 June By Investing.com - Investing.com South Africa
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Precigen, Inc.(NasdaqGS: PGEN) dropped from Russell 3000E Value Benchmark - marketscreener.com
Precigen: Entering The Oncology "Sweet Spot" (NASDAQ:PGEN) - Seeking Alpha
PGEN Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Precigen, Inc. – NASDAQ:PGEN - TradingView
Precigen Inc Actuals & Estimates (BX:I5X) - TradingView
Precigen Shareholders Expand Incentive Plan, Reaffirm Governance - The Globe and Mail
Precigen (PGEN) investors back 7M-share incentive pool and all board picks - Stock Titan
Clearfield And 2 Insider Picks For Strong Growth - simplywall.st
Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS TherapyWhat's Changed - Sahm
Precigen stock hits 52-week high at 5.47 USD By Investing.com - Investing.com Australia
Precigen stock hits 52-week high at 5.47 USD - Investing.com
Precigen Inc (PGEN) Institutional Confidence - TradingKey
Precigen (PGEN) Ends 11.6% Higher — This FDA Approval Could Hold the Reason - Insider Monkey
Precigen Gains FDA Orphan Drug Exclusivity for Gene Therapy Candidate PAPZIMEOSDebt Analysis Report - Město Břeclav
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS - Insider Monkey
Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win - Sahm
PGEN News | PRECIGEN INC (NASDAQ:PGEN) - ChartMill
Precigen Inc (PGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PGEN: All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions - TradingView
PGEN: All proposals, including board elections and compensation, passed overwhelmingly without dissent - TradingView
Precigen Inc Annual Shareholders Meeting Transcript - GuruFocus
Precigen Inc (PGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precigen Inc (PGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Precigen Inc (PGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Precigen Inc (PGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
5 Penny Stocks With Explosive Growth Potential - Insider Monkey
Precigen Inc (PGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Precigen Inc (PGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Precigen Inc (PGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
H.C. Wainwright Remains a Buy on Precigen (PGEN) - Insider Monkey
5 Best Penny Stocks That Could Skyrocket in 2026 - Insider Monkey
Precigen gains 7 year FDA orphan drug exclusivity - grafa.com
Precigen receives seven-year exclusivity for rare disease drug - Investing.com UK
Precigen receives seven-year exclusivity for rare disease drug By Investing.com - Investing.com India
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging - ACCESS Newswire
1.16%
0.48%
大文字化:
|
ボリューム (24 時間):